SEC Form 4 · accession 0001193125-26-257366
Trevi Therapeutics, Inc. · TRVI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Thomas Heffernan
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 4, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001563880
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonstatutory Stock Option (right to buy)F1 | $13.45 | Jun 3, 2026 | A | 35,000 | A | — | Jun 2, 2036 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.